Lima J J, Boudoulas H, Blanford M
J Pharmacol Exp Ther. 1981 Dec;219(3):741-7.
Disopyramide binds to two independent sites on protein in human plasma. The first binding site located on alpha-1-acid glycoprotein has an association and a capacity constant of 1.0 x 10(6) M-1 and 3.5 x 10(-6) M, respectively, and accounts for the majority of disopyramide binding. The second site is probably located on albumin and accounts for 5 to 10% of the binding. The bound fraction of disopyramide was concentration-dependent at drug concentrations reported to be therapeutic. After administration of 100, 150, 200 and 300 mg doses of disopyramide (Norpace) to each of four human volunteers, the area under the free (unbound) disopyramide serum-concentration time curve averaged 2.32, 3.33, 5.21 and 8.24 mg/l. hr, respectively, and was directly proportional to dose. The elimination half-lives based on free and total drug concentrations averaged 4.36 and 6.51 hr, respectively (P less than .001), and were dose-independent. The peak response (change in pre-ejection period) and area under the response time curves were better related to free than to total serum concentrations of disopyramide.
丙吡胺与人血浆中的蛋白质有两个独立的结合位点。第一个结合位点位于α-1-酸性糖蛋白上,其结合常数和容量常数分别为1.0×10⁶ M⁻¹和3.5×10⁻⁶ M,丙吡胺的大部分结合都由此位点介导。第二个位点可能位于白蛋白上,占结合量的5%至10%。在报道的治疗药物浓度下,丙吡胺的结合分数呈浓度依赖性。给四名人类志愿者分别服用100、150、200和300 mg剂量的丙吡胺(诺佩斯)后,游离(未结合)丙吡胺血清浓度-时间曲线下面积分别平均为2.32、3.33、5.21和8.24 mg/l·小时,且与剂量成正比。基于游离和总药物浓度的消除半衰期分别平均为4.36和6.51小时(P<0.001),且与剂量无关。峰值反应(射血前期变化)和反应时间曲线下面积与丙吡胺的游离血清浓度比与总血清浓度的相关性更好。